BTAI Relative Valuation
BTAI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BTAI is overvalued; if below, it's undervalued.
Historical Valuation
BioXcel Therapeutics Inc (BTAI) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.92. The fair price of BioXcel Therapeutics Inc (BTAI) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：2.07
Fair
-0.50
PE
1Y
3Y
5Y
Trailing
Forward
-1.84
EV/EBITDA
BioXcel Therapeutics Inc. (BTAI) has a current EV/EBITDA of -1.84. The 5-year average EV/EBITDA is -2.59. The thresholds are as follows: Strongly Undervalued below -7.16, Undervalued between -7.16 and -4.88, Fairly Valued between -0.31 and -4.88, Overvalued between -0.31 and 1.97, and Strongly Overvalued above 1.97. The current Forward EV/EBITDA of -1.84 falls within the Historic Trend Line -Fairly Valued range.
-2.20
EV/EBIT
BioXcel Therapeutics Inc. (BTAI) has a current EV/EBIT of -2.20. The 5-year average EV/EBIT is -2.54. The thresholds are as follows: Strongly Undervalued below -6.96, Undervalued between -6.96 and -4.75, Fairly Valued between -0.32 and -4.75, Overvalued between -0.32 and 1.89, and Strongly Overvalued above 1.89. The current Forward EV/EBIT of -2.20 falls within the Historic Trend Line -Fairly Valued range.
31.39
PS
BioXcel Therapeutics Inc. (BTAI) has a current PS of 31.39. The 5-year average PS is 72.57. The thresholds are as follows: Strongly Undervalued below -181.80, Undervalued between -181.80 and -54.61, Fairly Valued between 199.75 and -54.61, Overvalued between 199.75 and 326.93, and Strongly Overvalued above 326.93. The current Forward PS of 31.39 falls within the Historic Trend Line -Fairly Valued range.
-0.55
P/OCF
BioXcel Therapeutics Inc. (BTAI) has a current P/OCF of -0.55. The 5-year average P/OCF is -3.19. The thresholds are as follows: Strongly Undervalued below -10.40, Undervalued between -10.40 and -6.80, Fairly Valued between 0.41 and -6.80, Overvalued between 0.41 and 4.02, and Strongly Overvalued above 4.02. The current Forward P/OCF of -0.55 falls within the Historic Trend Line -Fairly Valued range.
-0.55
P/FCF
BioXcel Therapeutics Inc. (BTAI) has a current P/FCF of -0.55. The 5-year average P/FCF is -3.27. The thresholds are as follows: Strongly Undervalued below -10.26, Undervalued between -10.26 and -6.76, Fairly Valued between 0.23 and -6.76, Overvalued between 0.23 and 3.73, and Strongly Overvalued above 3.73. The current Forward P/FCF of -0.55 falls within the Historic Trend Line -Fairly Valued range.
BioXcel Therapeutics Inc (BTAI) has a current Price-to-Book (P/B) ratio of -0.43. Compared to its 3-year average P/B ratio of 4.02 , the current P/B ratio is approximately -110.69% higher. Relative to its 5-year average P/B ratio of 3.74, the current P/B ratio is about -111.49% higher. BioXcel Therapeutics Inc (BTAI) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -271.98%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -169.13% , the current FCF yield is about -100.00% lower.
-0.47
P/B
Median3y
4.02
Median5y
3.74
-139.37
FCF Yield
Median3y
-271.98
Median5y
-169.13
Competitors Valuation Multiple
The average P/S ratio for BTAI's competitors is 0.00, providing a benchmark for relative valuation. BioXcel Therapeutics Inc Corp (BTAI) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -54.21%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BTAI decreased by 65.06% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -6.38K to -31.54K.
The secondary factor is the Revenue Growth, contributed -54.21%to the performance.
Overall, the performance of BTAI in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is BioXcel Therapeutics Inc (BTAI) currently overvalued or undervalued?
What is BioXcel Therapeutics Inc (BTAI) fair value?
How does BTAI's valuation metrics compare to the industry average?
What is the current P/B ratio for BioXcel Therapeutics Inc (BTAI) as of Dec 05 2025?
What is the current FCF Yield for BioXcel Therapeutics Inc (BTAI) as of Dec 05 2025?
What is the current Forward P/E ratio for BioXcel Therapeutics Inc (BTAI) as of Dec 05 2025?